Immunome Stock (NASDAQ:IMNM)

Forecast Revenue Ownership Financials Chart

Previous Close

$15.69

52W Range

$5.15 - $17.32

50D Avg

$11.77

200D Avg

$9.73

Market Cap

$1.44B

Avg Vol (3M)

$1.24M

Beta

1.95

Div Yield

IMNM Company Profile

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

131

IPO Date

Oct 02, 2020

Website

IMNM Performance

IMNM Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$9.04M	$14.02M	-
Operating Income	$-305.80M	$-109.53M	$-36.90M
Net Income	$-292.96M	$-106.81M	$-37.51M
EBITDA	$-151.35M	$-28.27M	$-36.27M
Basic EPS	$-5.00	$-5.38	$-3.09
Diluted EPS	$-5.00	$-5.38	$-3.09

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
NUVB	Nuvation Bio Inc.
IMTX	Immatics N.V.
AMLX	Amylyx Pharmaceuticals, Inc.
SYRE	Spyre Therapeutics, Inc.
TSHA	Taysha Gene Therapies, Inc.
PRAX	Praxis Precision Medicines, Inc.
SNDX	Syndax Pharmaceuticals, Inc.
ORIC	ORIC Pharmaceuticals, Inc.
WVE	Wave Life Sciences Ltd.
TRML	Tourmaline Bio, Inc.